Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Induction and Maintenance Chemotherapy with Yoshi 864 plus Hormone Therapy with MPA for Adenocarcinoma of the Kidney in Adults

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

No phase specified

Treatment

Closed

16 to 80

NCI

SWOG-7805

Objectives

I.  Determine the response rate and survival of patients with metastatic 
adenocarcinoma of the kidney to combined therapy with Yoshi 864 and 
medroxyprogesterone acetate (MPA).

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients between 16 and 80 years of 
age with measurable, histologically proven recurrent or metastatic 
adenocarcinoma of the kidney.  Patients must have adequate hematological, 
renal and hepatic function.  Patients must have a life expectancy of more than 
90 days, have recovered from any previous therapy which may not have included 
study agents.

Expected Enrollment

Protocol closed 03/80.

Outline

Nonrandomized study.
Induction and Maintenance:  Single-agent Chemotherapy plus Hormone Therapy.  
Yoshi 864, Yoshi, NSC-102627; plus Medroxyprogesterone Acetate, MPA, NSC-26386.

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Charles Coltman, MD, Protocol chair(Contact information may not be current)
Ph: 210-567-2710

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.